This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
CONFIRM

ABOUT ACEPODIA

Powerful, Off-the-Shelf Cell Therapies Made Accessible

We are transforming cancer treatment with first-in-class cell therapies, with enhanced and targeted potency, improved safety and broad applicability across hematologic and solid tumor cancers. Our lead NK cell therapies are designed to offer countless patients a powerful anti-cancer therapeutic option.

TECHNOLOGY

  • Supercharged Cell Therapies
  • oNK Cells
  • ACC
  • NKγδT Cells
  • Supercharged Cell Therapies
    TECHNOLOGY

    Supercharged Cell Therapies

    Uniting Specialized Cancer Killing Immune Cells with Tumor Targeting Technologies

    Acepodia’s first-in-class cell therapies consist of proprietary immune cell lines with enhanced cytotoxic properties that are supercharged with cancer targeting technologies to maximize anti-cancer activity directly against tumors. The company’s lead product candidate is ACE1702, an off-the-shelf antibody-conjugated natural killer cell therapy in clinical development for the treatment of HER2-expressing solid tumors.

  • oNK Cells
    TECHNOLOGY

    oNK Cells

    Amplified Natural Killer Cells for Off-the-Shelf Cancer-Killing Potential

    oNK cells are a proprietary natural killer (NK) cell line that is derived from the 1-2% of NK cells that have enhanced cytotoxic properties through their over expression of activation receptors and very low expression of inhibitory receptors. oNK cells can be augmented using established and novel technologies to target and engage solid tumors and hematological malignancies.

  • ACC
    TECHNOLOGY

    ACC

    Linking Tumor-Targeting Antibodies

    Acepodia’s proprietary antibody cell-conjugation platform (ACC) uses live-cell compatible chemistry to attach tumor-targeting antibodies directly to the surface of immune cells to generate highly specific and potent cell therapies, without the need for genetic engineering. The ACC platform can significantly enhance the potency of immune cells, thereby addressing the current challenge of treating solid tumors with cellular therapy. Acepodia is utilizing its ACC technology with its oNK cells and gamma delta T cells.

  • NKγδT Cells
    TECHNOLOGY

    NKγδT Cells

    Eliciting a Robust Anticancer Immune Response

    Gamma delta (γδ) T cells have a unique T-cell receptor on their surface enabling them to participate in both adaptive and innate immune responses, but they represent only a small subset of T cells in peripheral blood. In addition to being inherently cytotoxic towards tumors, gamma delta T cells can recruit other immune cells to elicit a robust anti-cancer immune response. Acepodia is developing allogeneic NK-like gamma delta T cells for use in its cell therapy programs.

PIPELINE

PROMISING PIPELINE OF CELL THERAPIES

ACC

Program
Discovery
Preclinical
Phase I
Phase II
ACE1702
HER2 Targeting, ACC-oNK Cell Therapy
Phase I ​
ACE1831
CD20 Targeting, ACC-NKγδT Cell Therapy
Preclinical ​
ACE1708
PD-L1 Targeting, ACC-NKγδT Cell Therapy
Preclinical ​
ACE1975
Target undisclosed, ACC-NKγδT Cell Therapy
Preclinical ​
ACE2023
Target undisclosed, ACC-NKγδT Cell Therapy
Preclinical ​
ACE2107
Target undisclosed
Discovery ​
ACE2146
Target undisclosed
Discovery ​
Acepodia CEO and Co-founder, Sonny Hsiao, Ph.D., to Present at Allogeneic Cell Therapies Summit 2021
Allogeneic Cell Therapies Summit 2021

Acepodia CEO and Co-founder, Sonny Hsiao, Ph.D., to Present at Allogeneic Cell Therapies Summit 2021

Topic: Driving Persistence with Allogeneic Gamma-Delta T Cell Therapy